Denali Therapeutics (DNLI) Total Debt (2022)

Denali Therapeutics' (DNLI) quarterly Total Debt came in at $4.4 million in Q4 2022, up 204.09% on a QoQ basis from $1.4 million in Q3 2022.

Denali Therapeutics (DNLI) Total Debt (2022) Analysis & Trends

Denali Therapeutics (DNLI) has 1 years of Total Debt data on file, last reported at $4.4 million in Q4 2022.

On a quarterly basis, Total Debt changed N/A year-over-year to $4.4 million in Q4 2022; TTM through Dec 2022 was $4.4 million, a N/A change from a year earlier, with the FY2022 full-year figure at $4.4 million, changed N/A from the prior year.
Total Debt for Q4 2022 stood at $4.4 million, up from $1.4 million in the prior quarter.
Over the last five years, Total Debt for DNLI reached as high as $4.4 million in Q4 2022 and fell as low as $1.4 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	110.96 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	959.06 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Denali Therapeutics	4.33 Bn	4.33 Bn	-	-

Download Data